ArticleMagyar onkologia2026
[Data and clinical experience of patients undergoing sentinel lymph node biopsy between 2020 and 2025 at the National Institute of Oncology, Hungary].
Article in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe authors present a retrospective analysis of sentinel lymph node biopsy (SLNB) data from patients with primary cutaneous melanoma treated at the National Institute of Oncology.
methodsA total of 806 patients who underwent SLNB between 2020 and 2025 were included. Primary tumor characteristics were evaluated in relation to progression-free survival (PFS) and overall survival (OS) and, in SLNB-positive patients, the impact of adjuvant therapies was assessed.
resultsBreslow thickness showed a significant negative association with both PFS and OS. Significant differences in survival outcomes were also observed between SLNB-positive and SLNB-negative patients. Among SLNB-positive patients, no significant difference in PFS was detected between those receiving adjuvant therapy and those who did not, nor among different adjuvant modalities. However, adjuvant therapy was associated with a significant improvement in OS.
conclusionsAlthough our findings differ from results reported in clinical trials, longer follow-up is required for proper conclusions.
Indexed as
Identifiers
42730998PMC13577718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.